[go: up one dir, main page]

NO20092464L - Faste former av rasemisk ilaprazol - Google Patents

Faste former av rasemisk ilaprazol

Info

Publication number
NO20092464L
NO20092464L NO20092464A NO20092464A NO20092464L NO 20092464 L NO20092464 L NO 20092464L NO 20092464 A NO20092464 A NO 20092464A NO 20092464 A NO20092464 A NO 20092464A NO 20092464 L NO20092464 L NO 20092464L
Authority
NO
Norway
Prior art keywords
racemic ilaprazole
solid forms
ilaprazole
secretion
methyl
Prior art date
Application number
NO20092464A
Other languages
English (en)
Other versions
NO342530B1 (no
Inventor
John M Brackett
David T Jonaitis
Wei Lai
Stephan D Parent
Jih Hua Liu
Jinyu Shen
Original Assignee
Il Yang Pharm Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Il Yang Pharm Co Ltd filed Critical Il Yang Pharm Co Ltd
Publication of NO20092464L publication Critical patent/NO20092464L/no
Publication of NO342530B1 publication Critical patent/NO342530B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Foreliggende oppfinnelse gjelder krystallinske former av racemisk ilaprazol, 2[[(4-metoksy-3-metyl-2-pyridinyl)-metyl]sulfinyl]-5-(1H-pyrrol-1-yl)-lH-benzimidazol. Oppfinnelsen gjelder også et farmasøytisk preparat for inhibering av sekresjonen av magesyre som omfatter en krystallinsk form av ilaprazol ifølge oppfinnelsen i en mengde som effektivt inhiberer sekresjonen av magesyre og et farmasøytisk akseptabelt bærestoff. Oppfinnelsen tilveiebringer også fremgangsmåter for behandling av forskjellige syrerelaterte gastrointestinale (GI) forstyrrelser.
NO20092464A 2006-12-29 2009-06-29 Faste former av rasemisk ilaprazol NO342530B1 (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US87760806P 2006-12-29 2006-12-29
US88749907P 2007-01-31 2007-01-31
PCT/US2007/089127 WO2008083333A1 (en) 2006-12-29 2007-12-28 Solid state forms of racemic ilaprazole

Publications (2)

Publication Number Publication Date
NO20092464L true NO20092464L (no) 2009-09-28
NO342530B1 NO342530B1 (no) 2018-06-11

Family

ID=39313094

Family Applications (2)

Application Number Title Priority Date Filing Date
NO20092398A NO20092398L (no) 2006-12-29 2009-06-24 Krystallinske former av solvatisert ilaprazol
NO20092464A NO342530B1 (no) 2006-12-29 2009-06-29 Faste former av rasemisk ilaprazol

Family Applications Before (1)

Application Number Title Priority Date Filing Date
NO20092398A NO20092398L (no) 2006-12-29 2009-06-24 Krystallinske former av solvatisert ilaprazol

Country Status (18)

Country Link
US (4) US7999110B2 (no)
EP (2) EP2102191B1 (no)
JP (2) JP5315254B2 (no)
KR (3) KR101052387B1 (no)
CN (2) CN101687849B (no)
AU (2) AU2007341984B2 (no)
CA (2) CA2674347C (no)
DK (1) DK2102192T3 (no)
ES (1) ES2398846T3 (no)
IL (2) IL199234A (no)
MX (2) MX2009006530A (no)
MY (2) MY146462A (no)
NO (2) NO20092398L (no)
NZ (2) NZ577509A (no)
PL (1) PL2102192T3 (no)
PT (1) PT2102192E (no)
RU (2) RU2464270C2 (no)
WO (2) WO2008083333A1 (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101144600B1 (ko) * 2009-12-08 2012-05-16 일양약품주식회사 일라프라졸의 결정형 ａ, ｂ의 제조방법 및 이들 결정형의 변환방법
CN103204843B (zh) * 2012-01-13 2014-12-31 丽珠医药集团股份有限公司 结晶型艾普拉唑钠乙醇化物及其制备方法
CN103204842B (zh) * 2012-01-13 2014-10-15 丽珠医药集团股份有限公司 结晶型艾普拉唑钠水合物及其制备方法
WO2013114232A1 (en) * 2012-02-02 2013-08-08 Lupin Limited Process for preparation of crystalline form l of ilaprazole
CN102746275B (zh) * 2012-06-21 2014-07-16 丽珠医药集团股份有限公司 结晶型艾普拉唑钠及其制备方法
CN102746277B (zh) * 2012-06-21 2014-05-14 丽珠医药集团股份有限公司 一种结晶形式的艾普拉唑钠及其制备方法
CN103172618B (zh) * 2013-02-27 2014-09-03 丽珠医药集团股份有限公司 艾普拉唑晶型及其制备方法
CN104370886B (zh) * 2014-11-18 2016-05-18 宁夏康亚药业有限公司 艾普拉唑晶型及其制备方法和应用
CN105055342A (zh) * 2015-08-13 2015-11-18 青岛蓝盛洋医药生物科技有限责任公司 一种治疗消化性溃疡的药物艾普拉唑钠组合物冻干粉针剂
CN105055343A (zh) * 2015-08-31 2015-11-18 青岛蓝盛洋医药生物科技有限责任公司 一种治疗胃病的药物艾普拉唑钠组合物冻干粉针剂
CN106749191A (zh) * 2016-12-10 2017-05-31 珠海保税区丽珠合成制药有限公司 艾普拉唑晶型ⅱ及其制备方法
KR101961028B1 (ko) * 2017-10-12 2019-03-21 중앙대학교 산학협력단 일라프라졸을 유효성분으로 함유하는 급성 위염의 예방 또는 치료용 약학 조성물
KR102332996B1 (ko) * 2020-04-13 2021-12-01 중앙대학교 산학협력단 일라프라졸을 유효성분으로 함유하는 장폐색증 예방 또는 치료용 약학조성물
KR20220065235A (ko) 2020-11-13 2022-05-20 주식회사 파마코스텍 일라프라졸 혼형 결정의 신규한 제조방법
KR102250509B1 (ko) 2020-12-09 2021-05-11 유니셀랩 주식회사 새로운 일라프라졸/자일리톨 공결정
KR20210019469A (ko) 2021-02-02 2021-02-22 주식회사 파마코스텍 일라프라졸 나트륨 결정형 및 신규한 제조방법
CN117050060A (zh) * 2023-07-20 2023-11-14 浙江美诺华药物化学有限公司 一种艾普拉唑晶型f的制备方法
KR20250156870A (ko) 2024-04-25 2025-11-04 엠에프씨 주식회사 일라프라졸 마그네슘염 수화물의 제조방법
CN119462610A (zh) * 2024-11-06 2025-02-18 甘肃皓天科技股份有限公司 一种艾普拉唑新晶型及其制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR0179401B1 (ko) * 1994-02-28 1999-03-20 송택선 신규한 5-피롤릴-2-피리딜메틸설피닐벤즈이미다졸 유도체
US6331539B1 (en) 1999-06-10 2001-12-18 3M Innovative Properties Company Sulfonamide and sulfamide substituted imidazoquinolines
RU2232159C2 (ru) * 1999-07-29 2004-07-10 Регентский Совет Университета Калифорнии Производные бензимидазола и фармацевтические композиции, содержащие пролекарство ингибитора протонного насоса
US6627646B2 (en) * 2001-07-17 2003-09-30 Sepracor Inc. Norastemizole polymorphs
CA2480352A1 (en) 2002-03-27 2003-10-09 Teva Pharmaceutical Industries Ltd. Lansoprazole polymorphs and processes for preparation thereof
ATE528301T1 (de) 2005-03-25 2011-10-15 Livzon Pharmaceutical Group Verfahren zur herstellung von substituierten sulfoxidzusammensetzungen
EP1879577A1 (en) * 2005-05-04 2008-01-23 AstraZeneca AB Proton pump inhibitors in the treatment of sleep disturbance due to silent gastro-esophageal reflux

Also Published As

Publication number Publication date
CA2674358A1 (en) 2008-07-10
RU2466129C2 (ru) 2012-11-10
CA2674347A1 (en) 2008-07-10
AU2007341992A1 (en) 2008-07-10
JP2010514807A (ja) 2010-05-06
HK1140483A1 (en) 2010-10-15
RU2009122242A (ru) 2011-02-10
JP5315253B2 (ja) 2013-10-16
KR20090086121A (ko) 2009-08-10
AU2007341992B2 (en) 2012-07-05
EP2102191A1 (en) 2009-09-23
KR20110091594A (ko) 2011-08-11
RU2009122241A (ru) 2011-02-10
CN101687849A (zh) 2010-03-31
CN101687848A (zh) 2010-03-31
ES2398846T3 (es) 2013-03-22
US20110046184A1 (en) 2011-02-24
US8592600B2 (en) 2013-11-26
HK1140484A1 (en) 2010-10-15
KR20090086615A (ko) 2009-08-13
PL2102192T3 (pl) 2013-04-30
DK2102192T3 (da) 2013-03-04
CA2674347C (en) 2013-08-06
NO342530B1 (no) 2018-06-11
JP5315254B2 (ja) 2013-10-16
IL199242A (en) 2013-10-31
US20080200516A1 (en) 2008-08-21
PT2102192E (pt) 2013-01-23
RU2464270C2 (ru) 2012-10-20
CN101687849B (zh) 2013-05-29
WO2008083341A1 (en) 2008-07-10
CA2674358C (en) 2013-10-08
CN101687848B (zh) 2013-05-15
MY145936A (en) 2012-05-31
EP2102192B1 (en) 2012-11-14
WO2008083333A1 (en) 2008-07-10
US7999110B2 (en) 2011-08-16
KR101052387B1 (ko) 2011-07-28
MY146462A (en) 2012-08-15
AU2007341984A1 (en) 2008-07-10
JP2010514806A (ja) 2010-05-06
IL199234A (en) 2013-07-31
US20110082174A1 (en) 2011-04-07
EP2102191B1 (en) 2012-11-21
MX2009006530A (es) 2009-08-18
US7989632B2 (en) 2011-08-02
EP2102192A1 (en) 2009-09-23
NZ577129A (en) 2012-02-24
US20080200517A1 (en) 2008-08-21
MX2009006529A (es) 2009-08-18
NO20092398L (no) 2009-09-28
NZ577509A (en) 2012-01-12
US8592599B2 (en) 2013-11-26
AU2007341984B2 (en) 2012-07-05

Similar Documents

Publication Publication Date Title
NO20092464L (no) Faste former av rasemisk ilaprazol
PH12012500954A1 (en) Method for producing dabigatran etexilate
EA200970090A1 (ru) Модуляторы метаболизма и лечение связанных с ним расстройств
NO20083836L (no) N-hydroksyakrylamidforbindelser
NO20083923L (no) Pyrazolkinoloner er potente parp-inhibitorer
WO2008022286A3 (en) Small molecule inhibitors of kynurenine-3-monooxygenase
WO2008094992A3 (en) 2-aminopyridine derivatives useful as kinase inhibitors
NO20092584L (no) Farmasoytiske sammensetninger og deres fremgangsmater for anvendelse
EP2178870A4 (en) INDOL AND INDAZONE COMPOUNDS AS AN INHIBITORS OF CELL NECROSIS
IL196543A (en) Pyridazinone derivatives, pharmaceutical preparations containing them for use in the treatment of disorders
WO2009153665A3 (en) Inhibitors of the shiga toxins trafficking through the retrograde pathway
UA96308C2 (ru) Антагонисты рецептора глюкагона, композиция, которая содержит такие соединения, и их применение
WO2007096151A3 (en) Inhibitors of p38-kinase for treatment of pulmonary hypertension
WO2009064458A3 (en) Compositions for the treatment of inflammation of the gastrointestinal tract
WO2008040649A3 (en) Pyrazine-2-carboxamide derivatives as cb2 receptor modulators
TW200738729A (en) Heterocycles as nicotinic acid receptor agonists for the treatment of dyslipidemia
MX2009000080A (es) Derivados de bencimidazol como inhibidores selectivos de la bomba de acido.
NO20083708L (no) 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer
WO2007059230A3 (en) Substituted 1h-benzimidazole-4-carboxamides are potent parp inhibitors
TN2009000452A1 (en) [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof
WO2007138468A3 (en) Processes for the preparation of lansoprazole
ZA200903981B (en) Processes for the preparation of 3-(4-(2,4-difluorobenzyloxy-3-bromo-6-methyl-2-oxopyridin-1(2h)-yl)-n,4-dimethyl-benzamide
ATE399156T1 (de) Neue indol- oder benzimidazol-derivate
SE0302382D0 (sv) New salts II
MY145122A (en) Phenylacetic acid derivatives as cox-2 inhibitors